[1] |
国家心血管病中心. 中国心血管健康与疾病报告2022[M]. 北京:中国协和医科大学出版社,2023.
|
[2] |
IBANEZ B, JAMES S, AGEWALL S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2018, 39(2):119-177. DOI: 10.1093/eurheartj/ehx393.
|
[3] |
LAWTON J S, TAMIS-HOLLAND J E, BANGALORE S,et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2022, 79(2):e21-129. DOI: 10.1016/j.jacc.2021.09.006.
|
[4] |
MILAZZO V, COSENTINO N, GENOVESE S,et al. Diabetes mellitus and acute myocardial infarction:impact on short and long-term mortality[J]. Adv Exp Med Biol, 2021, 1307:153-169. DOI: 10.1007/5584_2020_481.
|
[5] |
RAY K K, COLHOUN H M, SZAREK M,et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes:a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(8):618-628. DOI: 10.1016/S2213-8587(19)30158-5.
|
[6] |
LUO E F, WANG D, YAN G L,et al. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention[J]. Cardiovasc Diabetol, 2019, 18(1):150. DOI: 10.1186/s12933-019-0957-3.
|
[7] |
|
[8] |
HE J N, YUAN S, SONG C X,et al. High triglyceride-glucose index predicts cardiovascular events in patients with coronary bifurcation lesions:a large-scale cohort study[J]. Cardiovasc Diabetol, 2023, 22(1):289. DOI: 10.1186/s12933-023-02016-x.
|
[9] |
REZKALLA S H, STANKOWSKI R V, HANNA J,et al. Management of no-reflow phenomenon in the catheterization laboratory[J]. JACC Cardiovasc Interv, 2017, 10(3):215-223. DOI: 10.1016/j.jcin.2016.11.059.
|
[10] |
KAUR G, BAGHDASARYAN P, NATARAJAN B,et al. Pathophysiology,diagnosis,and management of coronary No-reflow phenomenon[J]. Int J Angiol, 2021, 30(1):15-21. DOI: 10.1055/s-0041-1725979.
|
[11] |
KLONER R A, KING K S, HARRINGTON M G. No-reflow phenomenon in the heart and brain[J]. Am J Physiol Heart Circ Physiol, 2018, 315(3):H550-562. DOI: 10.1152/ajpheart.00183.2018.
|
[12] |
SOMUNCU M U, AKGUN T, CAKıR M O,et al. The elevated soluble ST2 predicts No-reflow phenomenon in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. J Atheroscler Thromb, 2019, 26(11):970-978. DOI: 10.5551/jat.48413.
|
[13] |
DAI C F, LIU M Y, ZHOU Y,et al. A score system to predict no-reflow in primary percutaneous coronary intervention:The PIANO Score[J]. Eur J Clin Invest, 2022, 52(2):e13686. DOI: 10.1111/eci.13686.
|
[14] |
ŞIMŞEK B, ÇıNAR T, TANıK V O,et al. The association of acute—to—chronic glycemic ratio with no-reflow in patients with ST—segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Kardiol Pol, 2021, 79(2):170-178. DOI: 10.33963/KP.15736.
|
[15] |
KOSMAS C E, BOUSVAROU M D, KOSTARA C E,et al. Insulin resistance and cardiovascular disease[J]. J Int Med Res, 2023, 51(3):3000605231164548. DOI: 10.1177/03000605231164548.
|
[16] |
|
[17] |
ADEVA-ANDANY M M, MARTÍNEZ-RODRÍGUEZ J, GONZÁLEZ-LUCÁN M,et al. Insulin resistance is a cardiovascular risk factor in humans[J]. Diabetes Metab Syndr, 2019, 13(2):1449-1455. DOI: 10.1016/j.dsx.2019.02.023.
|
[18] |
CHEN W Q, WANG S K, LV W,et al. Causal associations of insulin resistance with coronary artery disease and ischemic stroke:a Mendelian randomization analysis[J]. BMJ Open Diabetes Res Care, 2020, 8(1):e001217. DOI: 10.1136/bmjdrc-2020-001217.
|
[19] |
GHOLAP N N, ACHANA F A, DAVIES M J,et al. Long-term mortality after acute myocardial infarction among individuals with and without diabetes:a systematic review and meta-analysis of studies in the post-reperfusion era[J]. Diabetes Obes Metab, 2017, 19(3):364-374. DOI: 10.1111/dom.12827.
|
[20] |
ZHAO S R, HUANG R, LIU F,et al. Study on correlation between type 2 diabetes and no-reflow after PCI[J]. Dis Markers, 2022, 2022:7319277. DOI: 10.1155/2022/7319277.
|
[21] |
LEVINE G N, BATES E R, BLANKENSHIP J C,et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction:an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction[J]. J Am Coll Cardiol, 2016, 67(10):1235-1250. DOI: 10.1016/j.jacc.2015.10.005.
|
[22] |
YU Y, WU Y Q, WU X Y,et al. Risk factors for No-reflow in patients with ST-elevation myocardial infarction who underwent percutaneous coronary intervention:a case-control study[J]. Cardiol Res Pract, 2022, 2022:3482518. DOI: 10.1155/2022/3482518.
|
[23] |
TAHAPARY D L, PRATISTHITA L B, FITRI N A,et al. Challenges in the diagnosis of insulin resistance:focusing on the role of HOMA-IR and tryglyceride/glucose index[J]. Diabetes Metab Syndr, 2022, 16(8):102581. DOI: 10.1016/j.dsx.2022.102581.
|
[24] |
RAMDAS NAYAK V K, SATHEESH P, SHENOY M T,et al. Triglyceride glucose(TyG)index:a surrogate biomarker of insulin resistance[J]. J Pak Med Assoc, 2022, 72(5):986-988. DOI: 10.47391/JPMA.22-63.
|
[25] |
CHO Y K, HAN K D, KIM H S,et al. Triglyceride-glucose index is a useful marker for predicting future cardiovascular disease and mortality in young Korean adults:a nationwide population-based cohort study[J]. J Lipid Atheroscler, 2022, 11(2):178-186. DOI: 10.12997/jla.2022.11.2.178.
|
[26] |
ER L K, WU S, CHOU H H,et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals[J]. PLoS One, 2016, 11(3):e0149731. DOI: 10.1371/journal.pone.0149731.
|
[27] |
LIM J, KIM J, KOO S H,et al. Comparison of triglyceride glucose index,and related parameters to predict insulin resistance in Korean adults:an analysis of the 2007-2010 Korean National Health and Nutrition Examination Survey[J]. PLoS One, 2019, 14(3):e0212963. DOI: 10.1371/journal.pone.0212963.
|
[28] |
LEE J, KIM B, KIM W,et al. Lipid indices as simple and clinically useful surrogate markers for insulin resistance in the U.S. population[J]. Sci Rep, 2021, 11(1):2366. DOI: 10.1038/s41598-021-82053-2.
|
[29] |
LIU M, PAN J Y, MENG K,et al. Triglyceride-glucose body mass index predicts prognosis in patients with ST-elevation myocardial infarction[J]. Sci Rep, 2024, 14(1):976. DOI: 10.1038/s41598-023-51136-7.
|
[30] |
CHENG Y, FANG Z, ZHANG X X,et al. Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention:a retrospective study[J]. Cardiovasc Diabetol, 2023, 22(1):75. DOI: 10.1186/s12933-023-01794-8.
|